SEC Form 4 · accession 0001209191-19-018083
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kerri-Ann Millar
Officer — VP-Finance
Period of report
Mar 6, 2019
Accepted (ET)
Mar 8, 2019 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645460
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.42 | Mar 6, 2019 | A | 30,000 | A | — | Mar 6, 2029 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019.